- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab
- Drug
- Lead sponsor
- Sundar Jagannath
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 158
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- obinutuzumab (RO5072759), rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Obinutuzumab, Placebo, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Searcy, Arkansas • Fullerton, California + 11 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orange City, Florida + 13 more
- Conditions
- Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
- Interventions
- Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast
- Drug
- Lead sponsor
- Benjamin T Diamond, MD
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Neoplasms
- Interventions
- Paclitaxel, Copanlisib (BAY80-6946)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • New York, New York • Houston, Texas
- Conditions
- Leukemia, Acute Lymphoblastic Leukemia, ALL
- Interventions
- rituximab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Kansas City, Missouri
- Conditions
- Colonoscopy, Adjunct Anesthesia Medication
- Interventions
- Diphenhydramine, Placebo
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Lung Cancer
- Interventions
- cetuximab
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 157
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
- Conditions
- Postoperative Nausea and Vomiting (PONV), Nausea
- Interventions
- Aprepitant, Ondansetron, Promethazine, Dexamethasone
- Drug
- Lead sponsor
- Sergio Bergese
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- CoVid 19 Positive
- Interventions
- Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
- Drug
- Lead sponsor
- The Camelot Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Oncology Patients Receiving Chemotherapy
- Interventions
- Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 7
- States / cities
- Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
- Conditions
- Graft Rejection
- Interventions
- Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib, Acetaminophen, Antihistamine, Methylprednisolone
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Locally Advanced Malignant Neoplasm, Breast Cancer
- Interventions
- Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
- Drug · Other · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Rhabdomyosarcoma
- Interventions
- TAA-Specific CTLs
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Cancer, Solid Tumor
- Interventions
- IMC-1121B, Moxifloxacin, Diphenhydramine
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more
- Conditions
- Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
- Interventions
- Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Minneapolis, Minnesota
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
- Interventions
- Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
- Interventions
- darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Liver Transplantation
- Interventions
- Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Acute Urticaria
- Interventions
- JDP-205 Injection, Diphenhydramine
- Drug
- Lead sponsor
- JDP Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio